Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Fujirebio: Net Loss due to New Retirement Allowance Accounting
January 29, 2001
-
ARCHIVE Meiji Seika to Strengthen Its Overseas Business Structures: Vice President Ogawa
January 29, 2001
-
ARCHIVE PAJ President Uehara Stresses Importance of Self-medication
January 29, 2001
-
ARCHIVE National Burden Rate Can Be Reduced 10% Through Reform: Koseisho Study Team
January 29, 2001
-
ARCHIVE Council to Study Ways to Supply Drug Information to Public
January 29, 2001
-
ARCHIVE Jovi to Increase Its Member Stores to 3,000
January 29, 2001
-
ARCHIVE REGULATORY NEWS IN BRIEF
January 29, 2001
-
ARCHIVE JIRA Aims at Introducing Medical Devices Law
January 29, 2001
-
ARCHIVE Clinical Trial Support System Established in 5 Nat'l Univ.
January 29, 2001
-
ARCHIVE Olympus Aims at \100 Bil. Sales with Genomic Healthcare
January 29, 2001
-
ARCHIVE In vitro Fertilization Using Sperm, Ova from Third Parties to Be Approved
January 29, 2001
-
ARCHIVE Economy, Trade, Industry Ministry to Help Handicapped Persons Obtain Access to Internet
January 29, 2001
-
ARCHIVE Government to Refuse Disclosure of AIDS Study Group's Minutes
January 29, 2001
-
ARCHIVE NPO to Hold Fair to Help Elderly Participate in Social Activities
January 29, 2001
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 29, 2001
-
ARCHIVE Aiming at \100 Billion Sales in 2005: Mr Ogawa of Nippon Roche
January 29, 2001
-
ARCHIVE Most Patients Satisfied with Administration Method for Zithromac
January 29, 2001
-
ARCHIVE Schering-Plough, Shionogi to Comarket Antiallergic Claritin
January 29, 2001
-
ARCHIVE Phase III Comparative Study on Progressive Lung Cancer Begins
January 29, 2001
-
ARCHIVE Toho Ties Up with Tsuruhara Yoshii in Kumamoto
January 29, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…